DNMT3A and acute myeloid leukemia: Furthermore, mutations in DNMT3A are associated with a poor prognosis in AML and have hence been suggested to be taken into consideration for risk stratification.8, 12 The role of DNMT inhibitors in the treatment of myelodysplastic syndromes and AML has been addressed in multiple clinical trials: treatment with azacytidine resulted in a longer overall survival (OS), a lower transfusion frequency and a delay of transformation from myelodysplastic syndromes into AML.